1. Home
  2. ZLAB vs TMDX Comparison

ZLAB vs TMDX Comparison

Compare ZLAB & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

SELL

Current Price

$22.62

Market Cap

2.6B

Sector

Health Care

ML Signal

SELL

Logo TransMedics Group Inc.

TMDX

TransMedics Group Inc.

SELL

Current Price

$76.09

Market Cap

2.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ZLAB
TMDX
Founded
2013
1998
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.6B
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
ZLAB
TMDX
Price
$22.62
$76.09
Analyst Decision
Strong Buy
Buy
Analyst Count
12
13
Target Price
$33.14
★ $99.82
AVG Volume (30 Days)
★ 712.3K
702.1K
Earning Date
11-05-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
38.46
★ 382.18
EPS
N/A
★ 0.61
Revenue
$460,156,000.00
★ $605,494,000.00
Revenue This Year
N/A
$22.57
Revenue Next Year
$26.50
$17.85
P/E Ratio
★ N/A
$129.73
Revenue Growth
15.33
★ 37.13
52 Week Low
$15.96
$60.11
52 Week High
$30.00
$156.00

Technical Indicators

Market Signals
Indicator
ZLAB
TMDX
Relative Strength Index (RSI) 34.34 36.46
Support Level $16.97 $66.64
Resistance Level $27.14 $79.60
Average True Range (ATR) 1.03 3.56
MACD -0.36 -0.60
Stochastic Oscillator 9.48 8.84

Price Performance

Historical Comparison
ZLAB
TMDX

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: